2. BSC Chinese Meme Coin 'Lobster' Surges to a Short-term Market Cap of $27 Million, Up 30% in 1 Hour
Over the past 24 hours, the English community has shown active and intricate discussions across multiple dimensions. Mainstream topics are centered around stablecoin yields and potential competition with the banking system, as well as the rapid penetration of prediction markets at the political and institutional levels. In terms of ecosystem development, Solana continues to strengthen transaction and stablecoin infrastructure, Ethereum reflects on cross-chain identity and token mechanisms, Base and AI agent experiments bring forth new application explorations, while Perp DEX and prediction markets evolve in market structure and institutional participation.
2.《Circle Doubled in a Month, What Is the Market Betting On?》
In June of last year, Circle went public at $31 per share. Two weeks later, the stock price touched $299. Then, it dropped back to $50, a decrease of over 80%. Then, this year's February financial report came out, doubling in two weeks to $111 today. During the same period of doubling, Bitcoin dropped by 40%. The connection between Circle's stock price and the crypto market has been broken.
On-chain Fund Flow Last Week on March 12

This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.











